Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer by Chollet, P et al.
Prognostic signiﬁcance of a complete pathological response after
induction chemotherapy in operable breast cancer
P Chollet
1,2, S Amat*
,1,2, H Cure
1,2, M de Latour
1, G Le Bouedec
1, M-A Mouret-Reynier
1, J-P Ferriere
1,2,
J-L Achard
1, J Dauplat
1 and F Penault-Llorca
1,2
1Centre Jean Perrin, Bureau de Recherche Clinique, 58 Rue Montalembert, B.P.392, 63011 Clermont-Ferrand Cedex 1, France;
2INSERM U484,
Rue Montalembert, 63005 Clermont-Ferrand Cedex, France
Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete
response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of
patients found to have a pathological complete response in both the breast and axillary lymph nodes after neoadjuvant
chemotherapy for operable breast cancer. Our goal was also to determine whether the residual pathological size of the
tumour in breast could be correlated with pathological node status. Between 1982 and 2000, 451 consecutive patients were
registered into ﬁve prospective phase II trials. After six cycles, 396 patients underwent surgery with axillary dissection for 277
patients (69.9%). Pathological response was evaluated according to the Chevallier’s classiﬁcation. At a median follow-up of 8
years, survival was analysed as a function of pathological response. A pathological complete response rate was obtained in 60
patients (15.2%) after induction chemotherapy. Breast tumour persistence was signiﬁcantly related to positive axillary nodes
(P=5.10
76). At 15 years, overall survival and disease-free survival rates were signiﬁcantly higher in the group who had a
pathological complete response than in the group who had less than a pathological complete response (P=0.047 and P=0.024,
respectively). In the absence of pathological complete response and furthermore when there is a notable remaining
pathological disease, axillary dissection is still important to determine a major prognostic factor and subsequently, a second
non cross resistant adjuvant regimen or high dose chemotherapy could lead to a survival beneﬁt.
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Primary chemotherapy has become the standard treatment of
inﬂammatory and locally advanced breast cancer (LABC) and has
more recently been extended to the management of patients with
operable disease, eligible for mastectomy, mainly in order to
increase the rate of breast conservation. There are multiple aspects
regarding this treatment modality that have not been sufﬁciently
elucidated (De Lena et al, 1978; Hortobagyi et al, 1983; Lippman
et al, 1986; Scholl et al, 1994; Fisher et al, 1997, 1998). The clinical
response to neoadjuvant chemotherapy, which is commonly
reported, does not always accurately reﬂect the pathological
response: residual tumour is frequent in clinically complete
responses, and conversely some complete pathological responses
are found in good partial clinical responses. The residual in situ
carcinoma has unprecised prognostic signiﬁcance, and is taken into
account only in some pathological classiﬁcations, as that of Cheval-
lier et al (1993). It appears then of interest to study the clinical
prognostic value of the pathological response on patient outcome.
Chemotherapy has been given in the adjuvant or neoadjuvant
setting to destroy occult distant metastases and to improve the
disease-free survival. The induction chemotherapy has over adju-
vant treatment a triple advantage: (1) to allow an earlier systemic
treatment, even before local care; (2) to increase breast conserva-
tion rate; (3) to give an individual evaluation of its efﬁcacy.
However, the true consequences of these advantages are still uncer-
tain.
As for the third point, one can suppose that a complete response
should reﬂect the chemosensitivity of occult distant metastatic sites;
then patients who have a pathological complete response (pCR) in
both the primary breast tumour and axillary lymph nodes after
induction chemotherapy should have better overall and disease-free
survival rates, compared with patients with poor responses.
Currently, only a small number of studies have been published
concerning the outcome of patients with a pathological complete
response (pCR) of both the primary tumour and axillary lymph
nodes after neoadjuvant chemotherapy (Feldman et al, 1986;
Chevallier et al, 1993; Fisher et al, 1997, 1998; Pierga et al,
2000). Some clinical and biologic factors (nodal, status, age, stage,
estrogens receptor, tumour size) have been analysed for the poten-
tial predictive signiﬁcance of complete histologic clearance from
both the breast and axillary lymph nodes after primary chemother-
apy (Kuerer et al, 1999); patients with a pCR had initial tumours
that were more likely to be oestrogens receptor-negative and
anaplastic but of smaller size than those of patients with less than
a pCR.
In the current study, we propose an analysis of 451 operable
breast cancer patients who received neoadjuvant chemotherapy
into ﬁve successive phase II trials from the same institution,
designed to improve breast conservation and pCR rates with
the available drugs in association. The construction of these
C
l
i
n
i
c
a
l
Received 2 August 2001; revised 27 December 2001; accepted 22 January
2002
*Correspondence: S Amat; E-mail: Recherche.Clinique@cjp.u-clermont1.fr
British Journal of Cancer (2002) 86, 1041–1046
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comtrials was based on the association of ‘major’ drugs for breast
cancer, i.e. giving a response rate of at least 40% at conven-
tional dose in ﬁrst metastatic line: one to three major drugs
have been associated, also with less effective but highly
employed drugs as ﬂuorouracil, cyclophosphamide and metho-
trexate. However, Taxotere
1 alone has been tested, as it had
a better clinical activity than doxorubicin at the optimal dose
in ﬁrst line for metastatic patients (Khayat et al, 2001). The
pCR rates obtained have raised from 5.6 to 33.3%; all these
individual studies have been published (Belembaogo et al,
1992; Van Praagh et al, 1995, 2001; Chollet et al, 1997,
2000). The database of individual survival has been actualised
and pooled to explore the prognosis value of pCR on a large
number of patients. Our goal was also to determine whether
the pathological response in breast could be signiﬁcantly related
to axillary disease.
PATIENTS AND METHODS
Patient selection
Primary chemotherapy was indicated for operable breast cancer
histologically or cytologically documented, of 30 mm in diameter
or more, or situated in the central area of the nipple, and divided
into stage IIA, IIB, IIIA, and some IIIB, using the TNM UICC
(International Union against Cancer) (Sobin and Wittekind,
1997). The diagnosis was usually established by ﬁne-needle aspira-
tion or per cutaneous microbiopsy of the primary tumour and
clinically involved axillary lymph nodes. Patients with primary
inﬂammatory carcinoma or with a long clinical history of
‘neglected’ tumour in breast were excluded and offered enrolment
onto other treatment protocols. Before treatment, a core biopsy
with a ‘surecut’ needle conﬁrmed the pathological variety and
has been used to determine prognosis factors as hormonal recep-
tors, pathological SBR grade and cell cycle parameters (cells in S
phase, aneuploidy).
The staging work-up included a complete history and physical
examination, complete blood cell and platelet counts, blood chem-
istry analysis, CEA and CA 15.3, electrocardiography, chest
radiograph, abdominal ultrasonography, bone scan at presentation.
The local evaluation comprised clinical and echographic measure-
ment of tumour and nodes, a bilateral mammography, in some
cases a breast IRM, and was repeated every two or three cycles
of chemotherapy.
Treatment modalities
Between 1982 and 2000, the 451 consecutive patients treated by
primary chemotherapy for an operable breast cancer (median
diameter: 40 mm) were registered into ﬁve prospective phase II
trials of regimens containing:
– anthracyclin-based regimens: AVCF/M, doxorubicin/Adriamy-
cin
1, vincristine, ﬂuorouracil and cyclophosphamide plus or
minus methotrexate (164 patients); NEM, vinorelbine/Navel-
bine
1, epirubicin, methotrexate (112 patients); TNCF, theprubi-
cin/THPadriamycin
1, vinorelbine/Navelbine
1, ﬂuorouracil and
cyclophosphamide (69 patients);
– or a taxane alone: docetaxel/Taxotere
1 (86 patients);
– or anthracyclin plus navelbine and taxane (paclitaxel/Taxol
1):
NET (20 patients).
Table 1 gives the precise protocols for the ﬁve regimens, which
were administered for six cycles. The primary end points for the
induction chemotherapy regimens consisted of determination of
clinical and particularly pathological response rates, as reported
previously (Belembaogo et al, 1992; Van Praagh et al, 1995,
2001; Chollet et al, 1997, 2000).
The patient was informed of the therapeutic choice, and from
the TNCF protocol (i.e. for TNCF, Taxotere
1 and NET regimens)
gave informed written consent, as being included in a prospective
phase II trial according to the available new drugs at this date and
to the results of previous studies. Each patient was then entered
prospectively into the database and observed longitudinally. The
complete medical records of all of the patients were available for
review at the time of this analysis. Chemotherapy was administered
at 21- to 28-day intervals. Patients were operated after six cycles by
conservative surgery for good responders and modiﬁed radical
mastectomy (MRM) for nonresponders.
Locoregional radiotherapy was instituted within 6 weeks after
the completion of surgery or of chemotherapy, if adjuvant
chemotherapy was given. Postoperative irradiation treatment was
delivered to the chest wall, internal mammary lymph nodes, and
supraclavicular/ axillary lymph nodes. In case of important residual
disease, patients could receive additional courses of chemotherapy.
Finally, menopausal patients with hormonal receptor-positive
tumours received tamoxifen for 5 years. Five-year compliance with
tamoxifen therapy was greater than 90%.
Assessment of response
Clinical responses to neoadjuvant chemotherapy were classiﬁed by
the following criteria: complete response (CR), a total resolution of
the breast tumour and axillary adenopathy based on clinical, echo-
graphic and radiographic examinations; partial response (PR), a
50% or greater reduction of the product of the two largest perpen-
dicular dimensions of the breast mass and axillary adenopathy;
minor response (MR), a less than 50% reduction of the product
of the two largest perpendicular dimensions of the breast mass
and axillary adenopathy; no change in clinical status (NC); and
progressive disease (PD). Patients had initially a tattooing point
at the centre of tumour area to help the knowledge of the precise
tumoural site in case of complete response.
We used the pathological classiﬁcation of Chevallier et al (1993).
The pathological response to neoadjuvant chemotherapy was clas-
siﬁed as follows:
– class I: no evidence of residual tumour in the breast or axillary
lymph nodes,
– class II: only residual in situ carcinoma,
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Table 1 Dosing for the ﬁve regimens used in phase II trials
Protocol Treatment
AVCF/M Doxorubicin D1 30 mg m
2
(n=164 patients) Vincristine D1 1 mg m
2
Cyclophosphamide D2 to D5 300 mg m
2
Fluorouracil D2 to D5 400 mg m
2
When methotrexate is added D2 and D4 20 mg m
2
Every 3 weeks
NEM Vinorelbine/Navelbine
1 D1 and D8 25 mg m
2
(n=112 patients) Epirubicin D1 and D8 35 mg m
2
Methotrexate D1 and D8 20 mg m
2
Every 4 weeks
Taxotere (TXT) Docetaxel/Taxotere
1 100 mg m
2
(n=86 patients)
Every 3 weeks
TNCF Theprubicin/THP-adrimycin
1 D1 to D3 20 mg m
2
(n=69 patients) Vinorelbine/Navelbine
1 D1 and D4 25 mg m
2
Cyclophosphamide D1 to D4 300 mg m
2
Fluorouracil D1 to D4 400 mg m
2
Every 3 weeks
NET Vinorelbine/Navelbine
1 D1 and D8 20 mg m
2
(n=20 patients) Epirubicin D1 and D8 35 mg m
2
Paclitaxel/Taxol
1 D9 175 mg m
2
Every 3 weeks
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– class IV: histologically unmodiﬁed tumour.
A minimum of 10 sections from the region of the initial primary
tumour site was examined; pCR is usually considered as the sum
of classes I and II.
Follow-up and survival
During the ﬁrst 5 years of follow-up, patients had a history and
physical examination, complete blood count, liver function tests,
serum CEA and CA 15–3 every 6 months. During the next 10
years, patients had only these clinical examination and biology
every 6 months, and mammography performed at yearly intervals.
At any time, if the patient exhibited elevated liver function tests, an
abdominal computed tomographic scan or ultrasound of the liver
was obtained. Overall survival (OS) and disease-free survival
(DFS) were calculated from the date of diagnosis with Kaplan–
Meier method (Kaplan and Meier, 1958); the cut-off date was
May 22nd, 2001. The log-rank statistic was used for univariate
comparisons of survival end points (Mantel, 1966); two-tailed
results are reported. A stepwise Cox regression procedure was used
to classify the pathological response among main prognostic factor
(Cox, 1972). P of 0.05 or lower was considered statistically signiﬁ-
cant.
RESULTS
Table 2 lists the pretreatment patient and tumour characteristics
for the 451 patients. The median age was 49 years (range 25 to
80 years) and 247 out of the 451 patients (54.8%) were premeno-
pausal. The median largest diameter of the primary tumour was
40 mm for the entire group of patients. There were six (1.3%)
tumours of 20 mm or less [T1], 309 (68.5%) tumours more than
20 mm but no more than 50 mm [T2], 125 (27.7%) tumours more
than 50 mm [T3], 11 (2.5%) tumours of any size with direct exten-
sion to chest wall or skin [T4]. Only 171 (37.9%) of the patients
did not have clinically involved adenopathy [N0] at diagnosis.
Three hundred and thirty-eight patients (74.9%) had a stage II
disease [T1-2-3, N0-1, M0: no distant metastasis], 102 (22.6%) a
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Table 2 Patient characteristics, response to neoadjuvant chemotherapies, and adjuvant treatments
AVCF/M NEM TXT TNCF NET Overall
Characteristics n=164 n=112 n=86 n=69 n=20 n=451
Median age (years) 52.0 52.5 46.0 44.0 50.5 49.0
Number of patients (%)
Menopausal status
Pre-menopausal 80 (48.8) 50 (44.6) 48 (55.8) 58 (84.1) 11 (55.0) 247 (54.8)
Menopausal 84 (51.2) 62 (55.4) 38 (44.2) 11 (15.9) 9 (45.0) 204 (45.2)
Stage
IIa 48 (29.3) 43 (38.4) 33 (38.4) 14 (20.3) 6 (30.0) 144 (31.9)
IIb 83 (50.6) 47 (42.0) 26 (30.2) 34 (40.3) 4 (20.0) 194 (43.0)
IIIa 33 (20.1) 22 (19.6) 20 (23.3) 21 (30.4) 6 (30.0) 102 (22.6)
IIIb 0 (0) 0 (0) 7 (8.1) 0 (0) 4 (20.0) 11 (2.5)
Pathology
Invasive ductal 122 (74.4) 94 (83.9) 68 (79.1) 61 (88.4) 14 (70.0) 359 (79.6)
Invasive lobular 18 (11.0) 17 (15.2) 11 (12.8) 5 (7.3) 4 (20.0) 55 (12.2)
Others 24 (14.6) 1 (0.9) 7 (8.1) 3 (4.3) 2 (10.0) 37 (8.2)
SBR grading
I 14 (20.9) 26 (28.0) 4 (5.0) 2 (3.4) 0 (0) 46 (14.7)
II 40 (59.7) 47 (50.5) 35 (43.8) 25 (43.1) 9 (60.0) 156 (49.8)
III 13 (19.4) 20 (21.5) 41 (51.2) 31 (53.5) 6 (40.0) 111 (35.5)
Hormonal receptors
Positive 20 (24.1) 42 (45.7) 36 (47.4) 11 (22.0) 9 (47.4) 118 (36.9)
Negative 49 (59.0) 27 (29.3) 28 (36.8) 29 (58.0) 3 (15.8) 136 (42.5)
Clinical response n=146 n=111 n=82 n=69 n=17 n=425
Complete (CR) 19 (13.0) 15 (13.5) 14 (17.1) 24 (34.8) 2 (11.8) 74 (17.4)
Partial (PR) 65 (44.5) 66 (59.5) 44 (53.7) 31 (44.9) 12 (70.6) 218 (51.3)
Objective (CR+PR) 84 (57.5) 81 (72.9) 58 (70.7) 55 (79.7) 14 (82.4) 292 (68.7)
Less than partial 62 (42.5) 30 (27.1) 24 (29.3) 14 (20.3) 3 (17.6) 133 (31.3)
Surgery n=122 n=111 n=76 n=69 n=18 n=396
Conservative 70 (57.4) 90 (81.1) 54 (71.0) 51 (73.9) 15 (83.3) 280 (70.7)
MRM 52 (42.6) 21 (18.9) 22 (29.0) 18 (26.1) 3 (16.7) 116 (29.3)
Pathological response n=122 n=111 n=76 n=69 n=18 n=396
Classes I and II 7 (5.7) 14 (12.6) 15 (19.7) 23 (33.3) 1 (5.6) 60 (15.2)
Classes III and IV 115 (94.3) 97 (87.4) 61 (80.3) 46 (66.7) 17 (94.4) 336 (84.8)
Adjuvant treatment n=163 n=111 n=76 n=69 n=18 n=437
Radiotherapy 157 (96.3) 110 (99.1) 76 (100.0) 57 (82.6) 17 (94.4) 417 (95.4)
Chemotherapy 40 (24.5) 11 (9.9) 36 (47.4) 10 (14.5) 2 (11.1) 99 (22.7)
Hormonotherapy 74 (45.4) 60 (54.1) 32 (42.1) 25 (36.2) 7 (38.9) 198 (45.3)
Neoadjuvant chemotherapy with AVCF/M (doxorubicin, vincristine, cyclophosphamide, ﬂuorouracil+methotrexate), NEM (vinorelbine, epiru-
bicin, methotrexate), TXT (docetaxel), TNCF (theprubicin, vinorelbine, cyclophosphamide, 5-ﬂuorouracil), NET (vinorelbine, epirubicin,
paclitaxel); SBR, Scarff-Bloom-Richardson grading in patients with invasive ductal carcinoma; MRM, Modiﬁed Radical Mastectomy. The totals
for patients treated are not always equal to 451, due to the presence of certain nonmeasurable characteristics (n=21), withdrawal for drug
allergies (n=3) and toxicities (n=2). Moreover, 52 patients had not undergone surgery: 42 patients treated by AVCF/M who received radio-
therapy alone, six patients with disease progression, two patients who refused surgery after a clinical complete response and two who are
still under therapy.
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N0-1, M0]. Pathological proof of microbiopsy gave 358 (79.6%)
invasive ductal and 55 invasive lobular carcinomas, with 35.5%
of SBR grade III tumours (n=111). Tumour oestrogens receptor
status at diagnosis was determined before treatment in 325 patients
(72.1%), and the progesterone receptor status was determined in
321 patients (71.2%).
Tumour response to neoadjuvant chemotherapy
Because of technical reasons or incomplete treatments, 36 patients
were inevaluable for response (18 AVCF/M, 1 NEM, 3 NET and 4
Taxotere
1). Clinical response was consequently determined in 425
patients (Table 2). Two hundred and eighteen patients (51.3%) had
at least a partial response and 74 (17.4%) a complete response,
allowing an overall clinical response rate of 68.7% but the percen-
tage was variable according to the relative potency of the treatment
used.
Fifty-ﬁve patients could not be included for the pathological
evaluation after six courses: 42 AVCF/M treated by radiotherapy
alone (initially good responders were not immediately operated,
they have been considered as invaluable for pathological response),
three acute allergies to Taxotere
1, six progressions, two surgery
refusals after clinical complete response, two too early. Then, 396
patients underwent either a segmental mastectomy (n=280,
70.7%) or a modiﬁed radical mastectomy (n=116, 29.3%) after
six cycles of chemotherapy; 277 (70.0%) patients had an axillary
dissection after chemotherapy (Table 2).
According to the Chevallier classiﬁcation after cases review, 40
patients had a class I, 20 a class II, 107 a class III and 229 a class
IV, allowing a pCR rate of 15.2% (60 of the 396 operated patients);
the percentage of pCR was also variable according to the effective-
ness of the regimen used: from 5.6% with NET to 33.3% with the
semi-intensive TNCF regimen. As adjuvant treatment, 417 patients
received radiotherapy, 99 a second chemotherapy, and 198 received
tamoxifen (Table 2).
Pathological response and survival
The patients have been included from January 1982 to May 2000
and median follow-up reached 8 years as of May 22nd, 2001.
The OS and DFS were analysed as a function of pathological
response after neoadjuvant chemotherapy (Figure 1). Survival was
evaluated in patients with pCR (classes I and II) and was compared
to nonresponders survival (classes III and IV). Similarly, survival of
patients with class I response was compared with that of patients
with classes II, III and IV responses.
Patients with pCR had an improved 15-year DFS compared with
that of patients with incomplete tumour responses (classes III and
IV responses) with a P value of 0.0053. When class I was consid-
ered alone against other classes, the difference was still signiﬁcant
(Figure 1A: log-rank; w
2=5.076, P=0.024). The difference observed
between the responders and nonresponders was due to 35.4%
relapses in the class III and IV group vs only 18.3% in patients with
pCR.
Conversely, the 15-year OS was not signiﬁcantly different in
patients with pCR when it was compared with the group of
patients with residual invasive tumours (classes III and IV), with
a P value of 0.37. However, when class I was considered alone
against other classes, the difference became signiﬁcant (Figure 1B:
log-rank; w
2=3.950, P=0.047). This appeared to be due to lesser
results in the class II group. Conversely, OS in class I was about
85.1% at 15 years vs around 66.7% in the other classes.
The Cox regression analysis showed that prognostic factors of
survival were node involvement (P54.10
73) followed by SBR
grade (P50.04), and pathological type for DFS only (P=0.012).
Pathological response did not seem to inﬂuence survival in multi-
variate analysis (P=0.11 for DFS and P=0.96 for OS).
Pathological response and nodes involvement
Positive axillary nodes are the main prognostic factor in breast
cancer; our goal was to determine whether the pathological
response in breast was signiﬁcantly related to axillary disease.
The residual pathological size of the tumour at surgery was evalu-
ated when possible, i.e. in 255 out of the 277 patients who
underwent axillary dissection. On univariate analysis, the residual
tumour size was found to be correlated with node involvement.
The pathological response in breast was strongly correlated with
pathological node status with a 3.1-fold increased relative risk of
involvement for patients with remaining tumour in breast
(P=5.10
76). Twenty-eight patients (80.0%), who had no residual
tumour in breast at surgery, were negative for axillary disease
compared with 85 patients (38.8%) in the nonresponders group.
No signiﬁcant correlation between the residual tumour size and
prognosis was found (P=0.31).
DISCUSSION
A pCR in the breast and axilla can be obtained in up to 33% of the
cases, as a function of treatment used, in operable breast cancer
(Hortobagyi et al, 1983; Lippman et al, 1986; Scholl et al, 1994;
Schwartz et al, 1994; Powles et al, 1995; Brain et al, 1997; Bona-
donna et al, 1998; Fisher et al, 1998; Morrell et al, 1998; Kuerer
et al, 1999). It is known that neoadjuvant chemotherapy is able
to convert clinically involved lymph nodes to a pathologically nega-
tive status in 25–38% of breast tumours. However currently, only
a small number of studies have been published concerning the
outcome of patients with a pCR of both the primary tumour
and axillary lymph nodes after neoadjuvant chemotherapy (Feld-
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Figure 1 Analyse of the disease-free survival (A) and overall survival (B)
as a function of pathological response after neoadjuvant chemotherapy.
Pathological response was evaluated according to Chevallier’s classiﬁcation
(Chevallier et al, 1993). Survival was analysed in patients with Class I
response vs in patients with Classes II, III, IV responses.
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The results of our study indicate that in treating an operable
breast cancer greater than 30 mm in diameter, neoadjuvant
chemotherapy can completely clear the breast and axillary lymph
nodes of any microscopic evidence of invasive tumour, as assessed
by standard histologic examination. This was observed in 60 out of
396 patients operated after chemotherapy (15.2%). The complete
tumour clearance (pCR) must be considered in breast and axilla
as a new prognosis factor with putative individual value, early
postulated in the study of Feldman et al (1986). Only a few papers
have been published concerning the incidence and outcome of
patients with a pCR in the primary tumour and axillary lymph
nodes after neoadjuvant chemotherapy (Machiavelli et al, 1998;
Kuerer et al, 1999). Most of the literature concerning pCR rates
after induction treatment refers to and reports on pCRs in the
primary tumour alone (Schwartz et al, 1994; Morrell et al, 1998;
Bonadonna et al, 1998). In the National Surgical Adjuvant Breast
and Bowel Project B-18 trial (Fisher et al, 1997, 1998), 13 (7%)
of the 185 operable patients with clinically positive axillary lymph
nodes treated with neoadjuvant chemotherapy were found to have
no residual invasive tumour in the breast and axillary tissue upon
pathological examination. However, pCR was documented only in
clinically complete responses and, it is known that it can be found
in a proportion of good partial clinical responses.
Does a pCR after chemotherapy simply identify patients who
have a biologically predetermined excellent prognosis, or can the
early initiation of systemic therapy alter the course of the disease,
as compared with conventional primary surgical intervention
followed by chemotherapy? Most trials of neoadjuvant chemother-
apy followed by local therapy vs local therapy followed by
postoperative chemotherapy did not show any survival advantage
for patients who initially received chemotherapy (Schaake-Koning
et al, 1985; Mauriac et al, 1991; Scholl et al, 1994; Powles et al,
1995; Fisher et al, 1997, 1998; Cunningham et al, 1998). Conver-
sely, from the currently available data, it can be stated with some
conﬁdence that neoadjuvant chemotherapy does not bestow a
survival disadvantage.
The principal goal of our study was to determine if the patients
without any histologic evidence of residual invasive tumour, i.e.
patients with pCR after neoadjuvant chemotherapy, had a survival
better than patients with residual invasive tumour. Although a pCR
was not synonymous with a deﬁnitive cure, it can predict at the
individual level a more favourable outcome with a reduced relapse
rate. These potential patients should be in partial response after
four courses in order to spare them from additional ineffective
and toxic treatment. Conversely, one of the most striking beneﬁts
of neoadjuvant chemotherapy could rather be the identiﬁcation of
patients with a minimal response than the early identiﬁcation of
patients with an excellent response to chemotherapy. This new
prognostic factor offers the advantage of possible therapeutic
change compared with the adjuvant treatment, which is ‘blind’
and only based on statistical parameters. Actually, the residual
disease accounts for a worse prognosis and invites to perform clin-
ical studies evaluating prospectively the eventual role of a non
cross-resistant chemotherapy in those patients with unmodiﬁed
or important residual tumour in breast and nodes.
Because neoadjuvant chemotherapy is often effective in reducing
the size of the primary tumour and in downstaging the axilla from
positive to negative status, we wanted to determine whether patho-
logical response of the primary tumour to neoadjuvant
chemotherapy could be signiﬁcantly related to axillary disease. A
residual tumour disease in breast is more frequently associated with
positive nodes at axillary surgery (P=5.10
76). Thus, for responders
(no residual tumour), the chance of having histologically negative
nodes after neoadjuvant chemotherapy is very high (80.0%),
regardless of the ﬁndings by clinical examination at diagnosis. In
patients with residual tumour at surgery, the response lack of the
primary tumour coupled with signiﬁcant residual disease in the
lymph nodes underlines a more aggressive disease. These data
explained the fact that pCR, obtained in both breast and axilla
according to Chevallier’s classiﬁcation, was not an independent
prognostic factor. Thus, subgroup of patients at different risk of
relapse could be selected according to the pathological response
in breast and the number of involved nodes. Some authors
reported that responders might be good candidates to receive axil-
lary irradiation instead of axillary dissection for local control in the
axilla (Lenert et al, 1999). In contrast, poor responders to neoad-
juvant chemotherapy had a high incidence of histologically
positive nodes and are currently best served by axillary dissection.
However, axillary dissection remains important not only for nonre-
sponders but also for responders to make decision regarding
patient therapy and to improve local control of disease.
In summary, neoadjuvant chemotherapy is able to eradicate any
histologic evidence of invasive carcinoma in both the primary
breast tumour and axillary lymph nodes in approximately 15%
of operable patients. The data indicate that further efforts should
focus on elucidating the molecular mechanisms associated with this
response. Indeed, only the complete histologic elimination of inva-
sive disease confers a survival advantage; a deﬁnitive cure is not
warranted and consequently, in absence of pCR, a second non-
cross resistant adjuvant regimen or high dose chemotherapy could
result in a better patient outcome.
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